Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Effient(®) (prasugrel) compared with branded clopidogrel (Plavix(®)) was more cost effective, and in most cases cost saving. These results were published in Circulation on [...]

Effient(R) (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction (STEMI), or severe heart attack. The two 2009 focused updates for the clinical guidelines, jointly developed by the [...]

Viterbi School biomedical engineer and cardiologist Tzung John Hsiai hopes to develop a new tool to help clinicians distinguish cardiac emergencies requiring immediate surgery from chronic problems manageable with drugs and lifestyle change.

Ablynx [Euronext Brussels: ABLX] is pleased to announce it has been awarded ‘Most Successful Early Phase Trial’ at the 2009 Good Clinical Practice Journal’s (GCPj) Clinical Research Excellence Awards in London. The GCPj’s Awards recognise excellence in clinical research and development.

Launched in 1999, the Global Registry of Acute Coronary Events (GRACE) is the world’s largest international database tracking outcomes of patients presenting with acute coronary syndromes (ACS),including myocardial infarction or unstable angina. GRACE data are derived from 247 hospitals in North America, South America, Europe, Asia, Australia and New Zealand, and from more than 100,000 [...]